A digital platform for understanding genetic risks of heart diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore how genetic risk factors influence health decisions and lifestyle choices related to heart diseases, particularly coronary artery disease (CAD). Participants will receive a genetic risk score based on their 23andMe data, which ranks their genetic risk compared to global populations. By understanding their genetic predisposition, individuals may be better equipped to make informed health decisions. The study focuses on the interplay between genetic risk and controllable health behaviors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Customer of 23andMe willing to share their 23andMe data
* User of Apple mobile device

Exclusion Criteria:

* Under 18 years old

Where it's running

• Scripps Translational Science Institute
  La Jolla, California, United States Recruiting

Study contacts

• Study coordinator: Jennifer Wagner, RN
• Email: generank@scripps.edu
• Phone: 858-784-2028

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TRIFORMIS RESILIA heart valve real-world results in tricuspid disease

  A real-world, observational study to see how the Edwards TRIFORMIS RESILIA tricuspid heart valve performs in adults needing tricuspid valve replacement.

  Recruiting Edwards Lifesciences · Carmel, Indiana · NCT07684313

• Women-Focused Education in Cardiac Rehab

  This pilot test checks if a women-focused education program added to standard cardiac rehab is feasible and helps women improve heart-health knowledge, quality of life, and healthy behaviors.

  Recruiting University Health Network, Toronto · Barrie, Ontario and 2 other locations · NCT07550036

• Transitioning people with recurrent pericarditis to KPL-387 monotherapy dosing and administration

  This trial will try switching people with well-controlled recurrent pericarditis from their current therapies to KPL-387 alone for up to 16 weeks to see if symptoms and inflammation stay controlled and the drug is tolerable.

  Recruiting at 48 sites Phase 2 Kiniksa Pharmaceuticals International, plc · Phoenix, Arizona and 47 other locations · NCT07288216

• Coronary CT angiography–guided calcium modification during PCI for calcified coronary artery disease

  This study will see if using CT angiography to plan calcium treatment before stenting helps people with flow-limiting, calcified coronary artery disease have better stent results and faster procedures compared with the usual ultrasound-guided PCI while keeping similar safety.

  Recruiting at 10 sites Fundación EPIC · Boston, Massachusetts and 14 other locations · NCT07286578

• Freesolve resorbable magnesium scaffold vs. Xience stent for up to two new heart artery lesions

  This trial tests whether the Freesolve resorbable magnesium scaffold works as well as the Xience drug-eluting stent for treating up to two new coronary artery lesions in adults.

  Recruiting at 3 sites Teleflex · Washington D.C., District of Columbia and 2 other locations · NCT07258290

• Wearable cardiac monitoring for early arrhythmia detection and remote management

  This project will try a smartwatch-based system to spot arrhythmias early and help manage adults with chronic or recently treated heart problems.

  Recruiting University of Sao Paulo · São Paulo, São Paulo · NCT07174206

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.